Hims & Hers Health, Inc. · Healthcare
The price already needs more growth than analysts forecast, at both a 9% and an 8% discount rate.
At a 1.0% margin the price requires 41.0% 3y revenue CAGR against 23.7% consensus, a cushion of -46.5pt versus a 3pt correction cut. Price needs more growth than consensus at any nearby discount rate, so the correction has room to go further. Real consumer channel plus a high multiple; cut ~3 pts.
Would recover if: the cut profit outlook (2026-11-10) and FTC/regulatory actions bite further. We re-check this against analyst estimates every evening.
10 years, at a 1% margin analysts expect
+15.0%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
11 published targets, set before the drop
Linked to META
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 143% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 13, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits 14% below the median published target and at the 36th percentile by count, meaning the market leans bearish and has largely refused the bull case while absorbing the immediate shock of recent regulatory actions.
Does the FTC lawsuit and regulatory scrutiny permanently impair Hims' ability to convert its 73.8% gross margins into meaningful free cash flow, or is the current 3.2% FCF margin a temporary distortion that resolves as the company scales? The available data can measure consumer attention and unit volumes to see if the regulatory headlines are actually deterring users, but it cannot directly measure the legal outcomes or pricing power.
What the price refuses to pay for, and the full reconstruction, on the HIMS quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names